RankingsPricing
  1. US-listed companies
  2. Ultragenyx Pharmaceutical Inc.
  3. Financials
  4. Free cash flow

Ultragenyx Pharmaceutical Inc.RARE

Market cap
$3.1B
P/E ratio
SummaryFinancials
Period EndFree cash flow (Million USD)YoY (%)
Dec 31, 2024-422-18.76%
Dec 31, 2023-519+4.53%
Dec 31, 2022-497+20.59%
Dec 31, 2021-412+133.80%
Dec 31, 2020-176-52.43%
Dec 31, 2019-370+25.65%
Dec 31, 2018-295+14.81%
Dec 31, 2017-257+49.94%
Dec 31, 2016-171+54.30%
Dec 31, 2015-111+137.12%
Dec 31, 2014-47

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)